A tighter archive for life-science signals.
Search once, then narrow by source or topic.
<a href="https://www.fiercebiotech.com/biotech/chutes-ladders-gilead-abruptly-parts-ways-general-counsel" hreflang="en">Chutes & Ladders—Gilead abruptly parts ways with general counsel</a>
Gilead’s general counsel and EVP of corporate affairs Deborah Telman will hang up the gloves by Dec. 5, the company announced in a brief filing Nov. 15. Gilead didn’t o...
Financings for Nov. 25, 2025
BioWorld - Friday, December 26, 2025 To read the full story, subscribe or sign in. Financings for Nov. 25, 2025 Nov. 25, 2025 Biopharmas in Asia-Pacific raising money i...
Today's news in brief
Appointments and advancements for Dec. 24, 2025 New hires and promotions in the med-tech industry, including: Henry Schein. Financings for Dec. 24, 2025 Med-tech firms...
In the clinic for Nov. 24, 2025
BioWorld - Friday, December 26, 2025 To read the full story, subscribe or sign in. In the clinic for Nov. 24, 2025 Nov. 24, 2025 Clinical updates, including data readou...
Novo’s semaglutide fails in phase III Alzheimer’s trials
Novo Nordisk A/S’ wild card bet that its GLP-1 receptor agonist semaglutide could be used to treat Alzheimer’s disease has not paid off, with the company reporting two...
ICYMI: Week in review, Nov. 17-21, 2025
A quick look back at top stories.
Biggest gainers and losers for Nov. 17-21, 2025
BioWorld - Friday, December 26, 2025 To read the full article sign up for free or sign in. Biggest gainers and losers for Nov. 17-21, 2025 Nov. 24, 2025 The top 10 biop...
Med-tech gainers and losers for Nov. 17-21, 2025
BioWorld - Friday, December 26, 2025 To read the full story, subscribe or sign in. Med-tech gainers and losers for Nov. 17-21, 2025 Nov. 24, 2025 The top 10 med-tech st...
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page